China approves first antibody-based therapeutic agent for COVID-19

The State Administration for the Control of Pharmaceutical Products of the People’s Republic of China has approved the country’s first combination therapeutic agent against coronavirus based on neutralizing antibodies, Report informs citing TASS that a message on the agency’s website reads.

Beijing-based Tengsheng Huachuang Pharmaceutical Technology has applied for registration. The therapeutic agent is an injection solution. The components of the drug created on the basis of antibodies are called BRII-196 and BRII-198. The office said it is the first combination therapy approved in the PRC with independent intellectual property rights.

The therapeutic agent will be used to treat adults and adolescents from 12 to 17 years old.